Tumor Biology

, Volume 36, Issue 6, pp 4005–4016 | Cite as

Isothiocyanates: a class of bioactive metabolites with chemopreventive potential

  • Gaurav Kumar
  • Hardeep Singh Tuli
  • Sonam Mittal
  • Jitendra Kumar Shandilya
  • Anil Tiwari
  • Sardul Singh Sandhu


In recent years, growing interest has been focused on the field of chemoprevention using natural therapies. The reason to turn toward “natural” remedies is associated with diverse beneficial pharmacological properties of natural compounds. Isothiocyanates (ITCs), the major pharmacological active constituents of cruciferous vegetables, are derived from the enzymatic hydrolysis of glucosinolates (GSLs). ITCs govern many intracellular targets including cytochrome P 450 (CYP) enzymes, proteins involved in antioxidant response, tumorigenesis, apoptosis, cell cycle, and metastasis. Investigation of the mechanisms of anti-cancer drugs has given important information regarding the use of natural chemopreventive compounds. This extensive review covers various molecular aspects of the interactions of ITCs with their recognized cellular targets involved in cancer treatment in order to enhance anti-tumor outcome with decreased toxicity to patients.


Isothiocyanates Cancer Apoptosis Metastasis Tubulin 



The authors would like to acknowledge Kurukshetra University, Kurukshetra (India) for providing the requisite facilities to perform this study.

Conflicts of interest



  1. 1.
    Xiang WU, Zhou QH, Ke XU. Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol Sin. 2009;30:501–12.Google Scholar
  2. 2.
    Melchini A, Traka MH. Biological profile of erucin: a new promising anticancer agent from cruciferous vegetables. Toxins (Basel). 2010;2:593–12.Google Scholar
  3. 3.
    Lambrix V, Reichelt M, Mitchell-Olds T, Kliebenstein DJ, Gershenzon J. The Arabidopsis epithiospecifier protein promotes the hydrolysis of glucosinolates to nitriles and influences Trichoplusia ni Herbivory. Plant Cell. 2001;13:2793–807.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Halkier BA, Gershenzon J. Biology and biochemistry of glucosinolates. Annu Rev Plant Biol. 2006;57:303–33.PubMedGoogle Scholar
  5. 5.
    Gimsing AL, Kirkegaard JA. Glucosinolates and biofumigation: fate of glucosinolates and their hydrolysis products in soil. Phytochem Rev. 2009;8:299–10.Google Scholar
  6. 6.
    Rose P, Huang Q, Ong CN, Whiteman M. Broccoli and watercress suppress matrix metalloproteinase-9 activity and invasiveness of human MDA-MB-231 breast cancer cells. Toxicol Appl Pharm. 2005;209:105–13.Google Scholar
  7. 7.
    Brown KK, Blaikie FH, Smith RA, Tyndall JD, Lue H, Bernhagen J, et al. Direct modification of the proinflammatory cytokine macrophage migration inhibitory factor by dietary isothiocyanates. J Biol Chem. 2009;284:32425–33.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Yuesheng Z. The molecular basis that unifies the metabolism cellular uptake and chemopreventive activities of dietary isothiocyanates. Carcinogenesis. 2012;33:2–9.Google Scholar
  9. 9.
    Brown KK, Hampton MB. Biological targets of isothiocyanates. Biochim Biophys Acta. 1810;2011:888–94.Google Scholar
  10. 10.
    Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, Wu SH, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem. 2010;58:2935–42.PubMedGoogle Scholar
  11. 11.
    Hecht SS. Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev. 2000;32:395–411.PubMedGoogle Scholar
  12. 12.
    Smith TJ. Mechanisms of carcinogenesis inhibition by isothiocyanates. Expert Opin Investig Drugs. 2001;10:2167–74.PubMedGoogle Scholar
  13. 13.
    Conaway CC, Yang YM, Chung FL. Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr Drug Metab. 2002;3:233–55.PubMedGoogle Scholar
  14. 14.
    Guo Z, Smith TJ, Wang E, Sadrieh N, Ma Q, Thomas PE, et al. Effects of phenethyl isothiocyanate a carcinogenesis inhibitor on xenobiotic-metabolizing enzymes and nitrosamine metabolism in rats. Carcinogenesis. 1992;13:2205–10.PubMedGoogle Scholar
  15. 15.
    Smith TJ, Guo Z, Guengerich FP, Yang CS. Metabolism of 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. Carcinogenesis. 1996;17:809–13.PubMedGoogle Scholar
  16. 16.
    Nakajima M, Yoshida R, Shimada N, Yamazaki H, Yokoi T. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos. 2001;29:1110–3.PubMedGoogle Scholar
  17. 17.
    Goosen TC, Kent UM, Brand L, Hollenberg PF. Inactivation of cytochrome P450 2B1 by benzyl isothiocyanate a chemopreventive agent from cruciferous vegetables. Chem Res Toxicol. 2000;13:1349–59.PubMedGoogle Scholar
  18. 18.
    Hanlon N, Okpara A, Coldham N, Sauer MJ, Ioannides C. Modulation of rat hepatic and pulmonary cytochromes P450 and phase II enzyme systems by erucin, an isothiocyanate structurally related to sulforaphane. J Agric Food Chem. 2008;56:7866–71.PubMedGoogle Scholar
  19. 19.
    Cheung KL, Kong AN. Molecular targets of dietary phenethyl isothiocyanate and Sulforaphane for cancer chemoprevention. AAPS J. 2010;12:87–97.PubMedGoogle Scholar
  20. 20.
    La Marca M, Beffy P, Della Croce C, Gervasi PG, Iori R, Puccinelli E, et al. Structural influence of isothiocyanates on expression of cytochrome P450, phase II enzymes, and activation of Nrf2 in primary rat hepatocytes. Food Chem Toxicol. 2012;50:2822–30.PubMedGoogle Scholar
  21. 21.
    Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, et al. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res. 2001;480–481:305–15.PubMedGoogle Scholar
  22. 22.
    Tan XL, Spivack SD. Dietary chemoprevention strategies for induction of phase II xenobiotic-metabolizing enzymes in lung carcinogenesis: a review. Lung Cancer. 2009;65:129–37.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Kansanen E, Kivela AM, Levonen AL. Regulation of Nrf2-dependent gene expression by 15-deoxy-Delta12,14-prostaglandin J2. Free Radic Biol Med. 2009;47:1310–7.PubMedGoogle Scholar
  24. 24.
    Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011;16:123–40.PubMedGoogle Scholar
  25. 25.
    Kansanen E, Jyrkkanen HK, Levonen AL. Activation of stress signaling pathways by electrophilic oxidized and nitrated lipids. Free Radic Biol Med. 2012;52:973–82.PubMedGoogle Scholar
  26. 26.
    Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci. 2002;99:11908–13.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Fimognari C, Lenzi M, Hrelia P. Interaction of the isothiocyanate sulforaphane with drug disposition and metabolism: pharmacological and toxicological implications. Curr Drug Metab. 2008;9:668–78.PubMedGoogle Scholar
  28. 28.
    Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, et al. Sulforaphane inhibits extracellular intracellular and antibiotic-resistant strains of Helicobacter pylori and prevents benzo (a) pyrene-induced stomach tumors. Proc Natl Acad Sci. 2002;99:7610–5.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, et al. Inhibition of 712-dimethylbenz (a) anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res. 2006;66:8293–6.PubMedGoogle Scholar
  30. 30.
    Zhang Y, Talalay P. Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic phase 2 enzymes. Cancer Res. 1998;58:4632–9.PubMedGoogle Scholar
  31. 31.
    Abdull Razis AF, Bagatta M, De Nicola GR, Iori R, Ioannides C. Induction of epoxide hydrolase and glucuronosyl transferase by isothiocyanates and intact glucosinolates in precision-cut rat liver slices: importance of side chain substituent and chirality. Arch oxicol. 2011;85:919–27.Google Scholar
  32. 32.
    Kassahun K, Davis M, Hu P, Martin B, Baillie T. Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase I metabolites and glutathione conjugates. Chem Res Toxicol. 1997;10:1228–33.PubMedGoogle Scholar
  33. 33.
    Clarke JD, Hsu A, Riedl K, Bella D, Schwartz SJ, Stevens JF, et al. Bioavailability and inter-conversion of sulforaphane and erucin in human subjects consuming broccoli sprouts or broccoli supplement in a cross-over study design. Pharmacol Res. 2011;64:456–63.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Yu R, Chen C, Mo YY, Hebbar V, Owuor ED, Tan TH, et al. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J Biol Chem. 2000;275:39907–13.PubMedGoogle Scholar
  35. 35.
    Yu R, Lei W, Mandlekar S, Weber MJ, Der CJ, Wu J, et al. Role of a mitogen activated protein kinase pathway in the induction of phase II detoxifying enzymes by hemicals. J Biol Chem. 1999;274:27545–52.PubMedGoogle Scholar
  36. 36.
    Hu R, Hebbar V, Kim BR, Chen C, Winnik B, Buckley B, et al. In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J Pharmacol Exp Ther. 2004;310:263–71.PubMedGoogle Scholar
  37. 37.
    Tuli HS, Sandhu SS, Sharma AK, Kashyap D. Cordycepin: a bioactive metabolite with therapeutic potential. Life Sci. 2013;93:863–9.PubMedGoogle Scholar
  38. 38.
    Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase 9 complex initiates an poptotic protease cascade. Cell. 1997;91:479–89.PubMedGoogle Scholar
  39. 39.
    Yu R, Mandlekar S, Harvey KJ, Ucker DS, Kong AN. Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease activity. Cancer Res. 1998;58:402–8.PubMedGoogle Scholar
  40. 40.
    Singh AV, Xiao D, Lew KL, Dhir R, Singh SV. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis. 2004;25:83–90.PubMedGoogle Scholar
  41. 41.
    Basu A, Haldar S. Dietary isothiocyanate mediated apoptosis of human cancer cells is associated with Bcl-xL phosphorylation. Int J Oncol. 2008;33:657–63.PubMedGoogle Scholar
  42. 42.
    Xiao D, Singh SV. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res. 2002;62:3615–9.PubMedGoogle Scholar
  43. 43.
    Hu R, Kim BR, Chen C, Hebbar V, Kong AN. The roles of JNK and apoptotic signaling pathways in PEITC mediated responses in human HT-29 colon adenocarcinoma cells. Carcinogenesis. 2003;24:1361–7.PubMedGoogle Scholar
  44. 44.
    Lui VWY, Wentzel AL, Xiao D, Lew KL, Singh SV, Grandis JR. Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma. Carcinogenesis. 2003;24:1705–12.PubMedGoogle Scholar
  45. 45.
    Xu K, Thornalley PJ. Signal transduction activated by the cancer chemopreventive isothiocyanates: cleavage of BID protein tyrosinase phosphorylation and activation of JNK. Brit J Cancer. 2001;84:670–3.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Xiao D, Srivastava SK, Lew KL, Zeng Y, Hershberger P, Johnson CS, et al. Allyl isothiocyanate a constituent of cruciferous vegetables inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis. 2003;24:891–7.PubMedGoogle Scholar
  47. 47.
    Chen YR, Wang W, Kong AN, Tan TH. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem. 1998;273:1769–75.PubMedGoogle Scholar
  48. 48.
    Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G, Hrelia P. Growth inhibition cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis. 2002;23:581–6.PubMedGoogle Scholar
  49. 49.
    Srivastava SK, Xiao D, Lew KL, Hershberger P, Kokkinakis DM, Johnson CS, et al. Allyl isothiocyanate a constituent of cruciferous vegetables inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis. 2003;24:1665–70.PubMedGoogle Scholar
  50. 50.
    Devi JR, Thangam EB. Mechanisms of anticancer activity of sulforaphane from Brassica oleracea in HEp-2 human epithelial carcinoma cell line. Asian Pac J Cancer Prev. 2012;13:2095–100.PubMedGoogle Scholar
  51. 51.
    Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 2004;64:5767–74.PubMedGoogle Scholar
  52. 52.
    Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis. 2006;27:811–9.PubMedGoogle Scholar
  53. 53.
    Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W, Chiao JW. Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res. 2006;26:1225–30.PubMedGoogle Scholar
  54. 54.
    Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, et al. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol. 2006;28:1287–93.PubMedGoogle Scholar
  55. 55.
    Zhang Y, Tang L, Gonzalez V. Selected isothiocyanates rapidly induce growth inhibition of cancer cells. Mol Cancer Ther. 2003;2:1045–52.PubMedGoogle Scholar
  56. 56.
    Xiao D, Johnson CS, Trump DL, Singh SV. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther. 2004;3:567–75.PubMedGoogle Scholar
  57. 57.
    Visanji JM, Duthie SJ, Pirie L, Thompson DG, Padfield PJ. Dietary isothiocyanates inhibit Caco-2 cell proliferation and induce G2/M phase cell cycle arrest DNA damage and G2/M checkpoint activation. J Nutr. 2004;134:3121–6.PubMedGoogle Scholar
  58. 58.
    Singh SV, Herman-Antosiewicz A, Singh AV, Lew KL, Srivastava SK, Kamath R, et al. Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem. 2004;279:25813–22.PubMedGoogle Scholar
  59. 59.
    Pappa G, Bartsch H, Gerhäuser C. Biphasic modulation of cell proliferation by sulforaphane at physiologically relevant exposure times in a human colon cancer cell line. Mol Nutr Food Res. 2007;51:977–84.PubMedGoogle Scholar
  60. 60.
    Cheung KL, Khor TO, Yu S, Kong AN. PEITC induces G1 cell cycle arrest on HT-29 cells through the activation of p38 MAPK signaling pathway. AAPS J. 2008;10:277–81.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Ho E, Dashwood RH. Dietary manipulation of histone structure and function. World Rev Nutr Diet. 2010;101:95–102.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Batra S, Sahu RP, Kandala PK, Srivastava SK. Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol Cancer Ther. 2010;9:1596–608.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol. 2008;33:375–80.PubMedGoogle Scholar
  64. 64.
    Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem. 2001;276:32008–15.PubMedGoogle Scholar
  65. 65.
    Xu C, Shen G, Chen C, Gelinas C, Kong AN. Suppression of NF-?B and NF-?B-regulated gene expression by sulforaphane and PEITC through I?B? IKK pathway in human prostate cancer PC-3 cells. Oncogene. 2005;24:4486–95.PubMedGoogle Scholar
  66. 66.
    Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci. 2005;1056:218–33.PubMedGoogle Scholar
  67. 67.
    Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 2007;29:19–35.PubMedGoogle Scholar
  68. 68.
    Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006;25:6800–16.PubMedGoogle Scholar
  69. 69.
    Naugler WE, Karin M. NF-kappa B and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008;18:19–26.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Srivastava SK, Singh SV. Cell cycle arrest apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzy isothiocyanate against human pancreatic cancer cells. Carcinogenesis. 2004;25:1701–9.PubMedGoogle Scholar
  71. 71.
    Prawan A, Saw CL, Khor TO, Keum YS, Yu S, Hu L, et al. Anti-NF-kappaB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signaling. Chem Biol Interact. 2009;179:202–11.PubMedGoogle Scholar
  72. 72.
    Jeong WS, Kim IW, Hu R, Kong AN. Modulatory properties of various natural chemopreventive agents on the activation of NF kappaB signaling pathway. Pharm Res. 2004;21:661–70.PubMedGoogle Scholar
  73. 73.
    Boreddy SR, Pramanik KC, Srivastava SK. Molecular targets of benzyl isothiocyanates in pancreatic cancer. In: Srivastava SK, editor. Pancreatic cancer- molecular mechanism and targets. Europe: In tech; 2012. p. 193–213.Google Scholar
  74. 74.
    Wu X, Zhu Y, Yan H, Liu B, Li Y, Zhou Q, et al. Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells. BMC Cancer. 2010;10:269.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Heiss E, Gerhäuser C. Time-dependent modulation of thioredoxin reductase activity might contribute to sulforaphane mediated inhibition of NF-kappaB binding to DNA. Antioxid Redox Signal. 2005;7:1601–11.PubMedGoogle Scholar
  76. 76.
    Rose P, Won YK, Ong CN, Whiteman M. Beta-phenylethyl and 8-methylsulphinyloctyl isothiocyanates constituents of watercress suppress LPS induced production of nitric oxide and prostaglandin E2 in RAW 2647 macrophages. Nitric Oxide. 2005;12:237–43.PubMedGoogle Scholar
  77. 77.
    Woo KJ, Kwon TK. Sulforaphane suppresses lipopolysaccharide-induced cyclooxygenase-2 (COX-2) expression through the modulation of multiple targets in COX-2 gene promoter. Int Immunopharmacol. 2007;7:1776–83.PubMedGoogle Scholar
  78. 78.
    Bucala R. Identification of MIF as a new pituitary hormone and macrophage cytokine and its role in endotoxic shock. Immunol Lett. 1994;43:23–6.PubMedGoogle Scholar
  79. 79.
    Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci. 1996;93:7849–54.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol. 1998;280:85–102.PubMedGoogle Scholar
  81. 81.
    Bell JE. MIF keeps macrophages on guard. Nat Rev Immunol. 2002;2:70.PubMedGoogle Scholar
  82. 82.
    Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 2000;10:359–66.PubMedGoogle Scholar
  83. 83.
    Bifulco C, McDaniel K, Leng L, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des. 2008;14:3790–801.PubMedGoogle Scholar
  84. 84.
    Ouertatani-Sakouhi H, El-Turk F, Fauvet B, Roger T, Le Roy D, Karpinar DP, et al. A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor (MIF). Biochemistry. 2009;48:9858–70.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Healy ZR, Liu H, Holtzclaw WD, Talalay P. Inactivation of tautomerase activity of macrophage migration inhibitory factor by sulforaphane: a potential biomarker for anti-inflammatory intervention. Cancer Epidemiol Biomarkers Prev. 2011;20:1516–23.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Crichlow GV, Fan C, Keeler C, Hodsdon M, Lolis EJ. Structural interactions dictate the kinetics of macrophage migration inhibitory factor inhibition by different cancer preventive isothiocyanates. Biochemistry. 2012;51:7506–14.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct. 2001;30:397–420.PubMedGoogle Scholar
  88. 88.
    Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–65.PubMedGoogle Scholar
  89. 89.
    Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;96:643–9.Google Scholar
  90. 90.
    White E. Life death and the pursuit of apoptosis. Genes Dev. 1996;10:1–15.PubMedGoogle Scholar
  91. 91.
    Jackson SJ, Singletary KW. Sulforaphane inhibits human MCF-7 mammary cancer cell mitotic progression and tubulin polymerization. J Nutr. 2004;134:2229–36.PubMedGoogle Scholar
  92. 92.
    Azarenko O, Okouneva T, Singletary KW, Jordan MA, Wilson L. Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane. Carcinogenesis. 2008;29:2360–8.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Mi L, Xiao Z, Hood BL, Dakshanamurthy S, Wang X, Govind S, et al. Covalent binding to tubulin by isothiocyanates A mechanism of cell growth arrest and apoptosis. J Biol Chem. 2008;283:22136–46.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Mi L, Gan N, Cheema A, Dakshanamurthy S, Wang X, Yang DC, et al. Cancer preventive isothiocyanates induce selective degradation of cellular alpha- and beta-tubulins by proteasomes. J Biol Chem. 2009;284:17039–51.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Geng F, Tang L, Li Y, Yang L, Choi KS, Kazim AL, et al. Allyl isothiocyanate arrests cancer cells in mitosis and mitotic arrest in turn leads to apoptosis via Bcl-2 phosphorylation. J Biol Chem. 2011;286:32259–67.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Tuli HS, Sadhu SS, Sharma AK, Kashyap D. Anti-angiogenic activity of the extracted fermentation broth of an entomopathogenic fungus, Cordyceps militaris 3936. Int J Pharm Pharm Sci. 2014;6:581–3.Google Scholar
  97. 97.
    Battegay EJ. Angiogensis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73:333–46.PubMedGoogle Scholar
  98. 98.
    Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol. 1999;6:217–24.Google Scholar
  99. 99.
    Boreddy SR, Sahu RP, Srivastava SK. Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-a/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS One. 2011;6:e25799.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Xiao D, Singh SV. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res. 2007;67:2239–46.PubMedGoogle Scholar
  101. 101.
    Gupta B, Chiang L, Chae KM, Lee DH. Phenethyl isothiocyanate inhibits hypoxia-induced accumulation of HIF-1aand VEGF expression in human glioma cells. Food Chem. 2013;141:1841–6.PubMedGoogle Scholar
  102. 102.
    Gupta P, Adkins C, Lockman P, Srivastava SK. Metastasis of breast tumor cells to brain is suppressed by phenethyl isothiocyanate in a novel in vivo metastasis model. PLoS One. 2013;8:e67278.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Davis R, Singh KP, Kurzrock R, Shankar S. Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep. 2009;22:1473–8.PubMedGoogle Scholar
  104. 104.
    Lee SY, Moon SR. Sulforaphane inhibits ultraviolet B-induced matrix metalloproteinase expression in human dermal fibroblasts. Korean J Oriental Physiol Pathol. 2012;26:922–8.Google Scholar
  105. 105.
    Yang MD, Lai KC, Lai TY, Hsu SC, Kuo CL, Yu CS, et al. Phenethyl isothiocyanate inhibits migration and invasion of human gastric cancer AGS cells through suppressing MAPK and NF-ΚB signal pathways. Anticancer Res. 2010;30:2135–44.PubMedGoogle Scholar
  106. 106.
    Lai KC, Lu CC, Tang YJ, Chiang JH, Kuo DH, Chen FA, et al. Allyl isothiocyanate inhibits cell metastasis through suppression of the MAPK pathways in epidermal growth factor stimulated HT29 human colorectal adenocarcinoma cells. Oncol Rep. 2014;31:189–96.PubMedGoogle Scholar
  107. 107.
    Masutomi N, Oyoda KT, Shibutani M, Niho N, Uneyama C, Takahashi N, et al. Toxic effects of benzyl and allyl isothiocyanates and benzyl-isoform specific metabolites in the urinary bladder after a single intravesical application to rats. Toxicol Pathol. 2001;29:617–22.PubMedGoogle Scholar
  108. 108.
    Okazaki K, Umemura T, Imazawa T, Nishikawa A, Masegi T, Hirose M. Enhancement of urinary bladder carcinogenesis by combined treatment with benzyl isothiocyanate and N-butyl-N-(4-hydroxybutyl) nitrosamine in rats after initiation. Cancer Sci. 2003;94:948–52.PubMedGoogle Scholar
  109. 109.
    Ogawa K, Hirose M, Sugiura S, Cui L, Imaida K, Ogiso T, et al. Dose dependent promotion by phenylethyl isothiocyanate, a known chemopreventer, of two-stage rat urinary bladder and liver carcinogenesis. Nutr Cancer. 2001;40:134–9.PubMedGoogle Scholar
  110. 110.
    Ogawa K, Futakuchi M, Hirose M, Boonyaphiphat P, Mizoguchi Y, Miki T, et al. Stage and organ dependent effects of 1-O-hexyl-2,3,5-trimethylhydroquinone, ascorbic acid derivatives, n-heptadecane-8,10-dione and phenylethyl isothiocyanate in a rat multiorgan carcinogenesis model. Int J Cancer. 1998;76:851–6.PubMedGoogle Scholar
  111. 111.
    Sugiura S, Ogawa K, Hirose M, Takeshita F, Asamoto M, Shirai T. Reversibility of proliferative lesions and induction of non-papillary tumors in rat urinary bladder treated with phenylethyl isothiocyanate. Carcinogenesis. 2002;24:547–53.Google Scholar
  112. 112.
    Akagi K, Sano M, Ogawa K, Hirose M, Goshima H, Shirai T. Involvement of toxicity as an early event in urinary bladder carcinogenesis induced by phenethyl isothiocyanate, benzyl isothiocyanate, and analogues in F344 rats. Toxicol Pathol. 2003;31:388–96.PubMedGoogle Scholar
  113. 113.
    Langer P, Štolc V. Goitrogenic activity of allylisothiocyanate—a widespread natural mustard oil. Endocrinology. 1963;76:151–5.Google Scholar
  114. 114.
    Heaney RK, Fenwick GR. Natural toxins and protective factors in brassica species including rapeseed. Nat Toxins. 1995;3:233–7.PubMedGoogle Scholar
  115. 115.
    Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, et al. Safety tolerance and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer. 2006;55:53–62.PubMedGoogle Scholar
  116. 116.
    Cartea ME, Velasco P. Glucosinolates in Brassica foods: bioavailability in food and significance for human health. Phytochem Rev. 2008;7:213–29.Google Scholar
  117. 117.
    Kassie F, Parzefall W, Muskb S, Johnsonb I, Lamprecht C, Sontagc G, et al. Genotoxic effects of crude juices from Brassica vegetables and juices and extracts from phytopharmaceutical preparations and spices of cruciferous plants origin in bacterial and mammalian cells. Chem Biol Interact. 1996;102:1–16.PubMedGoogle Scholar
  118. 118.
    Kassie F, Pool-Zobel B, Parzefall W, Knasmüller S. Genotoxic effects of benzyl isothiocyanate, a natural chemopreventive agent. Mutagenesis. 1999;14:595–604.PubMedGoogle Scholar
  119. 119.
    Liu H, Zhi Y, Geng G, Yu Z, Xu H. Effect of phenethyl isothiocyanate given at different duration of gestation on the outcome of pregnancy in rats. Wei Sheng Yan Jiu. 2011;40:283–6.PubMedGoogle Scholar
  120. 120.
    Musk SRR, Johnson IT. The clastogenic effects of isothiocyanates. Mutat Res. 1993;300:111–7.PubMedGoogle Scholar
  121. 121.
    Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci EL. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst. 1999;91:605–13.PubMedGoogle Scholar
  122. 122.
    Feskanich D, Ziegler RG, Michaud DS, Giovannucci EL, Speizer FE, Willett WC, et al. Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women. J Natl Cancer Inst. 2000;92:1812–23.PubMedGoogle Scholar
  123. 123.
    Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:1403–9.PubMedGoogle Scholar
  124. 124.
    Smith T, Musk SR, Johnson LT. Ally1 isothiocyanate selectively kills undifferentiated HT29 cells in vitro and suppresses aberrant crypt foci in the colonic mucosa of rats. Biochem Soc Trans. 1996;24:381S.PubMedGoogle Scholar
  125. 125.
    Manesh C, Kuttan G. Effect of naturally occurring allyl and phenyl isothiocyanates in the inhibition of experimental pulmonary metastasis induced by B16F-10 melanoma cells. Fitoterapia. 2003;74:355–63.PubMedGoogle Scholar
  126. 126.
    Kuroiwa Y, Nishikawa A, Kitamura Y, Kanki K, Ishii Y, Umemura T, et al. Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. Cancer Lett. 2006;241:275–80.PubMedGoogle Scholar
  127. 127.
    Nishikawa A, Furukawa F, Uneyama C, Ikezaki S, Tanakamaru Z, Chung FL, et al. Chemopreventive effects of phenethyl isothiocyanate on lung and pancreatic tumorigenesis in N-nitrosobis (2-oxopropyl) amine treated hamsters. Carcinogenesis. 1996;17:1381–4.PubMedGoogle Scholar
  128. 128.
    Solt DB, Chang KW, Helenowski I, Rademaker AW. Phenethyl isothiocyanate inhibits nitrosamine carcinogenesis in a model for study of oral cancer chemoprevention. Cancer Lett. 2003;202:147–52.PubMedGoogle Scholar
  129. 129.
    Sugiura S, Ogawa K, Hirose M, Takeshita F, Asamoto M, Shirai T. Reversibility of proliferative lesions and induction of non-papillary tumors in rat urinary bladder treated with phenylethyl isothiocyanate. Carcinogenesis. 2003;24:547–53.PubMedGoogle Scholar
  130. 130.
    Conaway CC, Wang CX, Pittman B, Yang YM, Schwartz JE, Tian D, et al. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Res. 2005;65:8548–57.PubMedGoogle Scholar
  131. 131.
    Takagi H, Shibutani M, Uneyama C, Lee KY, Kato N, Inoue K, et al. Limited tumor-initiating activity of phenylethyl isothiocyanate by promotion with sodium l-ascorbate in a rat two-stage urinary bladder carcinogenesis model. Cancer Lett. 2005;219:147–53.PubMedGoogle Scholar
  132. 132.
    Ye B, Zhang YX, Yang F, Chen HL, Xia D, Liu MQ, et al. Induction of lung lesions in Wistar rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by aspirin and phenethyl isothiocyanate. BMC Cancer. 2007;7:1–10.Google Scholar
  133. 133.
    Stoner GD, Dombkowski AA, Reen RK, Cukovic D, Salagrama S, Wang LS, et al. Carcinogen-altered genes in rat esophagus positively modulated to normal levels of expression by both black raspberries and phenylethyl isothiocyanate. Cancer Res. 2008;68:6460–7.PubMedPubMedCentralGoogle Scholar
  134. 134.
    Powolny AA, Bommareddy A, Hahm ER, Normolle DP, Beumer JH, Nelson JB, et al. Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer. J Natl Cancer Inst. 2011;103:571–84.PubMedPubMedCentralGoogle Scholar
  135. 135.
    Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc min mice. FASEB J. 2006;20:506–8.PubMedPubMedCentralGoogle Scholar
  136. 136.
    Dinkova-Kostova AT, Jenkins SN, Fahey JW, Ye L, Wehage SL, Liby KT, et al. Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. Cancer Lett. 2006;240:243–52.PubMedGoogle Scholar
  137. 137.
    Gills JJ, Jeffery EH, Matusheski NV, Moon RC, Lantvit DD, Pezzuto JM. Sulforaphane prevents mouse skin tumorigenesis during the stage of promotion. Cancer Lett. 2006;236:72–9.PubMedGoogle Scholar
  138. 138.
    Shen G, Khor TO, Hu R, Yu S, Nair S, Ho CT, et al. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in Apc Min/+ mouse. Cancer Res. 2007;67:9937–44.PubMedGoogle Scholar
  139. 139.
    Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood). 2007;232:227–34.Google Scholar
  140. 140.
    Matsui TA, Murata H, Sakabe T, Sowa Y, Horie N, Nakanishi R, et al. Sulforaphane induces cell cycle arrest and apoptosis in murine osteosarcoma cells in vitro and inhibits tumor growth in vivo. Oncol Rep. 2007;18:1263–8.PubMedGoogle Scholar
  141. 141.
    Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, et al. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis. 2007;28:1485–90.PubMedGoogle Scholar
  142. 142.
    Dickinson SE, Melton TF, Olson ER, Zhang J, Saboda K, Bowden GT. Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer. Cancer Res. 2009;69:7103–10.PubMedPubMedCentralGoogle Scholar
  143. 143.
    Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, et al. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res. 2009;69:2117–25.PubMedPubMedCentralGoogle Scholar
  144. 144.
    Traka MH, Spinks CA, Doleman JF, Melchini A, Ball RY, Mills RD, et al. The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer. Mol Cancer. 2010;9:1–23.Google Scholar
  145. 145.
    Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 2010;70:5004–13.PubMedGoogle Scholar
  146. 146.
    Li Y, Zhang T, Korkaya H, Liu S, Lee HF, Newman B, et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res. 2010;16:2580–90.PubMedPubMedCentralGoogle Scholar
  147. 147.
    Priya DK, Gayathri R, Sakthisekaran D. Role of sulforaphane in the anti-initiating mechanism of lung carcinogenesis in vivo by modulating the metabolic activation and detoxification of benzo (a) pyrene. Biomed Pharmacother. 2011;65:9–16.Google Scholar
  148. 148.
    Priya DK, Gayathri R, Gunassekaran GR, Sakthisekaran D. Protective role of sulforaphane against oxidative stress mediated mitochondrial dysfunction induced by benzo (a) pyrene in female Swiss albino mice. Pulm Pharmacol Ther. 2011;24:110–7.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Gaurav Kumar
    • 1
  • Hardeep Singh Tuli
    • 2
  • Sonam Mittal
    • 3
  • Jitendra Kumar Shandilya
    • 4
  • Anil Tiwari
    • 4
  • Sardul Singh Sandhu
    • 5
  1. 1.Department of BiochemistryKurukshetra UniversityKurukshetraIndia
  2. 2.Department of MicrobiologyKurukshetra UniversityKurukshetraIndia
  3. 3.School of BiotechnologyJawaharlal Nehru UniversityNew DelhiIndia
  4. 4.Department of ImmunopathologyPGIMERChandigarhIndia
  5. 5.Department of Biological SciencesR. D. UniversityJabalpurIndia

Personalised recommendations